financetom
Business
financetom
/
Business
/
Software firm Crexendo's Q2 revenue beats analyst expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Software firm Crexendo's Q2 revenue beats analyst expectations
Aug 5, 2025 1:24 PM

Overview

* Crexendo ( CXDO ) Q2 revenue rises 13% yr/yr, beating analyst expectations

* Non-GAAP net income for Q2 beats estimates, reaching $2.9 mln

* Adjusted EBITDA for Q2 exceeds expectations

Outlook

* Crexendo ( CXDO ) aims to accelerate telecom services revenue through profitable sales initiatives

* Company plans to expand Oracle Cloud Infrastructure presence for future growth

* Crexendo ( CXDO ) remains focused on strategic, accretive acquisitions to enhance growth

* Company well-positioned for growth with robust cash position of $23.5 mln

Result Drivers

* SOFTWARE SOLUTIONS - 31% growth in software solutions revenue drives overall revenue increase, per CEO Jeff Korn

* STRATEGIC INITIATIVES - Closing international data centers and expanding Oracle Cloud Infrastructure presence to maintain cost discipline

* CASH POSITION - Robust cash position of $23.5 mln supports continued growth and strategic investments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $16.60 $16.20

Revenue mln mln (6

Analysts

)

Q2 Beat $2.90 $1.66

Adjusted mln mln (6

Net Analysts

Income )

Q2 Net $1.20

Income mln

Q2 Beat $2.80 $1.87

Adjusted mln mln (6

EBITDA Analysts

)

Q2 $2 mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the it services & consulting peer group is "buy"

* Wall Street's median 12-month price target for Crexendo Inc ( CXDO ) is $8.00, about 26.6% above its August 4 closing price of $5.87

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biomea Says Preclinical Results Show 'Robust' Weight Loss From Investigational Drug
Biomea Says Preclinical Results Show 'Robust' Weight Loss From Investigational Drug
Jun 18, 2025
08:12 AM EDT, 06/18/2025 (MT Newswires) -- Biomea Fusion ( BMEA ) said Wednesday that preclinical data for its investigational weight loss drug, BMF-650, showed robust weight loss and appetite suppression. The study, conducted with monkeys, showed 12% to 15% body weight reductions over 28 days, the company said. BMF-650 was well-tolerated, the company said, adding that plans to file...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Pan Global Says Intercepts Further Higher-Grade Gold and Copper Mineralization in Spain
Pan Global Says Intercepts Further Higher-Grade Gold and Copper Mineralization in Spain
Jun 18, 2025
08:10 AM EDT, 06/18/2025 (MT Newswires) -- Pan Global Resources ( PGZFF ) on Wednesday said new assay results for drillholes PVD03 and PVD04 completed in the maiden drill campaign at its 100%-owned Carmenes project located in northern Spain, expand the breccia-hosted gold zone to the east and north of the mine workings, and mineralization remains wide open. Higher-grade intervals...
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Treatment
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Treatment
Jun 18, 2025
08:12 AM EDT, 06/18/2025 (MT Newswires) -- Biogen (BIIB) said Wednesday it has begun dosing participants in a phase 3 trial to assess omaveloxolone for treating Friedreich ataxia, a rare neurodegenerative disorder, in children aged between 2 and 16 years. The study will assess the efficacy and safety of omaveloxolone in both ambulatory and non-ambulatory children, with participants randomized to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved